06 September
hosts a team from the pharmaceutical company Novartis
CERMEL recently hosted a team from Novartis, the Swiss pharmaceutical company which is currently developing a new drug against malaria called KAF156. Following the successful visit, the head of the team, Dr. Vasant «Vas» Narasimhan, the medical director and designated CEO of Novartis wrote an article in Fortune magazine in which he outlines the current situation in malaria drug development and the work being done at CERMEL.
Dr. Narasimhan also gave his personal impressions of the visit in an article published on LinkedIn. CERMEL is excited to be part of the development of KAF156 and looking forward to working in close partnership with the Novartis team.
fortune.com
linkedin.com